| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Republic of Korea | 134 | 2026 | 176 | 12.050 |
Why?
|
| Cancer Survivors | 20 | 2025 | 120 | 7.480 |
Why?
|
| Neoplasms | 41 | 2025 | 1372 | 6.710 |
Why?
|
| Risk Factors | 97 | 2026 | 5316 | 5.490 |
Why?
|
| Incidence | 56 | 2026 | 1380 | 5.150 |
Why?
|
| Cohort Studies | 67 | 2026 | 2575 | 4.590 |
Why?
|
| Diabetes Mellitus | 12 | 2025 | 541 | 3.850 |
Why?
|
| Arthritis, Rheumatoid | 7 | 2026 | 337 | 3.800 |
Why?
|
| Myocardial Infarction | 11 | 2025 | 915 | 3.620 |
Why?
|
| Middle Aged | 116 | 2026 | 17682 | 3.540 |
Why?
|
| Aged | 99 | 2026 | 14481 | 3.390 |
Why?
|
| Oncologists | 9 | 2019 | 19 | 3.300 |
Why?
|
| Stroke | 11 | 2025 | 1189 | 3.240 |
Why?
|
| Parkinson Disease | 6 | 2024 | 132 | 3.180 |
Why?
|
| Humans | 205 | 2026 | 63587 | 3.150 |
Why?
|
| Adult | 101 | 2026 | 16904 | 3.140 |
Why?
|
| Cardiovascular Diseases | 15 | 2025 | 844 | 3.100 |
Why?
|
| Caregivers | 13 | 2019 | 277 | 3.010 |
Why?
|
| Male | 132 | 2026 | 29967 | 3.000 |
Why?
|
| Female | 139 | 2026 | 32979 | 2.990 |
Why?
|
| Proportional Hazards Models | 26 | 2026 | 731 | 2.940 |
Why?
|
| Lung Neoplasms | 10 | 2025 | 686 | 2.710 |
Why?
|
| Spinal Cord Injuries | 4 | 2024 | 50 | 2.690 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2025 | 699 | 2.690 |
Why?
|
| Retrospective Studies | 46 | 2025 | 6646 | 2.680 |
Why?
|
| Early Detection of Cancer | 10 | 2025 | 324 | 2.570 |
Why?
|
| Breast Neoplasms | 8 | 2025 | 1208 | 2.510 |
Why?
|
| Tuberculosis | 9 | 2025 | 296 | 2.360 |
Why?
|
| Metabolic Syndrome | 5 | 2024 | 142 | 2.040 |
Why?
|
| Obesity | 10 | 2025 | 1235 | 1.990 |
Why?
|
| Depression | 13 | 2025 | 908 | 1.980 |
Why?
|
| Survivors | 10 | 2025 | 178 | 1.920 |
Why?
|
| Prostatic Neoplasms | 5 | 2025 | 418 | 1.910 |
Why?
|
| Surveys and Questionnaires | 29 | 2025 | 2704 | 1.900 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 8 | 2024 | 90 | 1.900 |
Why?
|
| Exercise | 8 | 2025 | 946 | 1.850 |
Why?
|
| Macular Degeneration | 4 | 2025 | 187 | 1.840 |
Why?
|
| Smoking Cessation | 4 | 2024 | 549 | 1.770 |
Why?
|
| Hair Follicle | 2 | 2025 | 34 | 1.750 |
Why?
|
| Healthcare Disparities | 7 | 2021 | 364 | 1.750 |
Why?
|
| Heart Failure | 5 | 2024 | 915 | 1.620 |
Why?
|
| Smoking | 11 | 2024 | 866 | 1.620 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2025 | 140 | 1.540 |
Why?
|
| Hip Fractures | 3 | 2024 | 77 | 1.540 |
Why?
|
| Case-Control Studies | 13 | 2026 | 1121 | 1.490 |
Why?
|
| Alcohol Drinking | 9 | 2023 | 314 | 1.470 |
Why?
|
| Risk Assessment | 16 | 2025 | 2045 | 1.450 |
Why?
|
| Databases, Factual | 17 | 2025 | 851 | 1.440 |
Why?
|
| Attitude | 3 | 2016 | 102 | 1.420 |
Why?
|
| Communication | 9 | 2019 | 580 | 1.390 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2024 | 232 | 1.390 |
Why?
|
| Family | 4 | 2017 | 242 | 1.380 |
Why?
|
| Physicians | 4 | 2018 | 475 | 1.340 |
Why?
|
| Colorectal Neoplasms | 3 | 2026 | 277 | 1.300 |
Why?
|
| Alzheimer Disease | 5 | 2023 | 722 | 1.290 |
Why?
|
| Atrial Fibrillation | 5 | 2024 | 838 | 1.280 |
Why?
|
| Brain Ischemia | 3 | 2023 | 421 | 1.230 |
Why?
|
| Physician-Patient Relations | 7 | 2018 | 423 | 1.200 |
Why?
|
| Neuromyelitis Optica | 6 | 2024 | 10 | 1.180 |
Why?
|
| Dementia, Vascular | 3 | 2023 | 11 | 1.170 |
Why?
|
| Dihydrotestosterone | 2 | 2025 | 19 | 1.150 |
Why?
|
| Registries | 8 | 2024 | 879 | 1.130 |
Why?
|
| Thyroid Neoplasms | 2 | 2025 | 74 | 1.080 |
Why?
|
| Wnt Signaling Pathway | 2 | 2025 | 81 | 1.080 |
Why?
|
| Attitude to Health | 5 | 2018 | 293 | 1.070 |
Why?
|
| Quality of Life | 13 | 2024 | 1241 | 1.050 |
Why?
|
| Blood Glucose | 4 | 2024 | 484 | 1.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2024 | 763 | 1.050 |
Why?
|
| Terminal Care | 4 | 2017 | 110 | 1.050 |
Why?
|
| Osteoporotic Fractures | 2 | 2024 | 34 | 1.040 |
Why?
|
| Stomach Neoplasms | 6 | 2024 | 83 | 1.010 |
Why?
|
| Primary Health Care | 3 | 2024 | 697 | 1.000 |
Why?
|
| Mass Screening | 7 | 2024 | 694 | 1.000 |
Why?
|
| Esophageal Neoplasms | 2 | 2024 | 86 | 0.990 |
Why?
|
| Dementia | 3 | 2024 | 262 | 0.980 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2025 | 142 | 0.980 |
Why?
|
| Disease Susceptibility | 2 | 2023 | 165 | 0.960 |
Why?
|
| Motivation | 3 | 2017 | 287 | 0.950 |
Why?
|
| Proteinuria | 1 | 2025 | 43 | 0.940 |
Why?
|
| Membrane Potential, Mitochondrial | 5 | 2025 | 30 | 0.940 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2025 | 136 | 0.940 |
Why?
|
| Iris Plant | 1 | 2025 | 1 | 0.930 |
Why?
|
| Rhizome | 1 | 2025 | 2 | 0.930 |
Why?
|
| Attitude of Health Personnel | 5 | 2018 | 606 | 0.930 |
Why?
|
| Solanum melongena | 1 | 2025 | 1 | 0.920 |
Why?
|
| Inositol | 1 | 2025 | 9 | 0.920 |
Why?
|
| Microvessels | 1 | 2025 | 19 | 0.910 |
Why?
|
| Urologic Neoplasms | 1 | 2025 | 19 | 0.910 |
Why?
|
| Follow-Up Studies | 13 | 2025 | 2467 | 0.910 |
Why?
|
| Amputation, Traumatic | 1 | 2025 | 11 | 0.900 |
Why?
|
| Polynucleotides | 1 | 2024 | 1 | 0.890 |
Why?
|
| Cosmetic Techniques | 1 | 2024 | 11 | 0.880 |
Why?
|
| Patients | 2 | 2016 | 113 | 0.880 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 1 | 2024 | 1 | 0.880 |
Why?
|
| Young Adult | 26 | 2025 | 4716 | 0.880 |
Why?
|
| Mammography | 2 | 2025 | 291 | 0.880 |
Why?
|
| Exosomes | 1 | 2025 | 48 | 0.870 |
Why?
|
| Ultraviolet Rays | 1 | 2025 | 137 | 0.850 |
Why?
|
| Multiple Sclerosis | 5 | 2024 | 219 | 0.840 |
Why?
|
| Skin | 3 | 2025 | 374 | 0.840 |
Why?
|
| Reactive Oxygen Species | 4 | 2025 | 224 | 0.830 |
Why?
|
| Weight Gain | 1 | 2025 | 168 | 0.820 |
Why?
|
| Endothelial Cells | 1 | 2025 | 188 | 0.820 |
Why?
|
| Psoriasis | 1 | 2024 | 57 | 0.810 |
Why?
|
| Plant Extracts | 1 | 2025 | 172 | 0.810 |
Why?
|
| Blood Pressure | 2 | 2023 | 513 | 0.800 |
Why?
|
| Sex Factors | 3 | 2024 | 974 | 0.800 |
Why?
|
| Antioxidants | 1 | 2025 | 252 | 0.790 |
Why?
|
| Cardiovascular System | 1 | 2023 | 40 | 0.780 |
Why?
|
| Kidney Failure, Chronic | 1 | 2024 | 206 | 0.780 |
Why?
|
| Postmenopause | 7 | 2025 | 237 | 0.780 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 259 | 0.770 |
Why?
|
| Hypertension | 4 | 2023 | 590 | 0.770 |
Why?
|
| Myocardial Ischemia | 1 | 2023 | 117 | 0.760 |
Why?
|
| Patient Preference | 3 | 2018 | 87 | 0.750 |
Why?
|
| Stroke Rehabilitation | 1 | 2023 | 50 | 0.740 |
Why?
|
| Lipopolysaccharides | 1 | 2025 | 624 | 0.740 |
Why?
|
| National Health Programs | 6 | 2023 | 19 | 0.740 |
Why?
|
| Paget Disease, Extramammary | 1 | 2021 | 3 | 0.740 |
Why?
|
| Vulvar Neoplasms | 1 | 2021 | 11 | 0.730 |
Why?
|
| Advance Directives | 3 | 2017 | 49 | 0.730 |
Why?
|
| Binge Drinking | 1 | 2022 | 36 | 0.720 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 66 | 0.690 |
Why?
|
| Spirituality | 2 | 2018 | 39 | 0.680 |
Why?
|
| Frailty | 1 | 2023 | 130 | 0.680 |
Why?
|
| Bronchiectasis | 3 | 2025 | 13 | 0.630 |
Why?
|
| Occult Blood | 1 | 2019 | 19 | 0.610 |
Why?
|
| Ageism | 1 | 2018 | 3 | 0.600 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 709 | 0.590 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 5483 | 0.590 |
Why?
|
| Fatty Liver | 3 | 2025 | 109 | 0.590 |
Why?
|
| Decision Making | 3 | 2024 | 411 | 0.590 |
Why?
|
| Advance Care Planning | 2 | 2017 | 65 | 0.570 |
Why?
|
| Pilot Projects | 6 | 2024 | 1016 | 0.560 |
Why?
|
| Melanoma | 1 | 2021 | 331 | 0.560 |
Why?
|
| Disclosure | 2 | 2015 | 56 | 0.560 |
Why?
|
| Age Factors | 5 | 2024 | 1565 | 0.560 |
Why?
|
| Peer Review | 1 | 2018 | 26 | 0.560 |
Why?
|
| Awards and Prizes | 1 | 2018 | 33 | 0.550 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2024 | 697 | 0.540 |
Why?
|
| Curriculum | 1 | 2021 | 602 | 0.540 |
Why?
|
| Liver Neoplasms | 4 | 2023 | 301 | 0.540 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 174 | 0.540 |
Why?
|
| Cross-Sectional Studies | 16 | 2024 | 2588 | 0.530 |
Why?
|
| Health Promotion | 1 | 2021 | 500 | 0.530 |
Why?
|
| Pulmonologists | 1 | 2017 | 5 | 0.530 |
Why?
|
| Neoplasm Staging | 5 | 2020 | 518 | 0.520 |
Why?
|
| Professional-Family Relations | 1 | 2017 | 90 | 0.500 |
Why?
|
| Longitudinal Studies | 8 | 2025 | 1259 | 0.500 |
Why?
|
| Cells, Cultured | 3 | 2025 | 2158 | 0.490 |
Why?
|
| Hospice Care | 1 | 2017 | 68 | 0.490 |
Why?
|
| Health Care Costs | 2 | 2015 | 215 | 0.490 |
Why?
|
| Health Personnel | 2 | 2017 | 377 | 0.480 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2017 | 71 | 0.480 |
Why?
|
| Health Status Disparities | 3 | 2024 | 145 | 0.480 |
Why?
|
| Comorbidity | 11 | 2025 | 1117 | 0.470 |
Why?
|
| Solifenacin Succinate | 1 | 2015 | 1 | 0.460 |
Why?
|
| Ureteral Calculi | 1 | 2015 | 8 | 0.460 |
Why?
|
| Ureteroscopy | 1 | 2015 | 17 | 0.460 |
Why?
|
| Weight Reduction Programs | 1 | 2015 | 57 | 0.460 |
Why?
|
| Taiwan | 2 | 2025 | 12 | 0.450 |
Why?
|
| Smartphone | 1 | 2015 | 69 | 0.450 |
Why?
|
| Dermis | 2 | 2025 | 18 | 0.450 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2025 | 505 | 0.450 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 49 | 0.440 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2025 | 16 | 0.440 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2023 | 179 | 0.430 |
Why?
|
| Sulfonamides | 1 | 2015 | 127 | 0.420 |
Why?
|
| Mobile Applications | 1 | 2015 | 137 | 0.420 |
Why?
|
| Students | 1 | 2015 | 219 | 0.410 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 144 | 0.410 |
Why?
|
| Wound Healing | 2 | 2025 | 188 | 0.410 |
Why?
|
| Oxidative Stress | 2 | 2025 | 297 | 0.400 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 332 | 0.400 |
Why?
|
| Postural Balance | 4 | 2022 | 65 | 0.400 |
Why?
|
| Referral and Consultation | 1 | 2016 | 427 | 0.380 |
Why?
|
| Decision Support Techniques | 2 | 2024 | 193 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 1648 | 0.370 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 254 | 0.360 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2025 | 105 | 0.360 |
Why?
|
| Menopause | 3 | 2023 | 258 | 0.350 |
Why?
|
| Body Mass Index | 4 | 2024 | 869 | 0.350 |
Why?
|
| Adolescent | 9 | 2025 | 6260 | 0.350 |
Why?
|
| Stents | 1 | 2015 | 498 | 0.340 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 435 | 0.330 |
Why?
|
| Severity of Illness Index | 6 | 2024 | 1556 | 0.330 |
Why?
|
| Time Factors | 7 | 2025 | 3732 | 0.330 |
Why?
|
| Prognosis | 7 | 2024 | 1746 | 0.320 |
Why?
|
| Psychometrics | 4 | 2025 | 384 | 0.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 215 | 0.310 |
Why?
|
| Health Expenditures | 2 | 2022 | 122 | 0.300 |
Why?
|
| Perception | 5 | 2018 | 175 | 0.290 |
Why?
|
| Premenopause | 3 | 2025 | 60 | 0.290 |
Why?
|
| Anxiety | 3 | 2024 | 429 | 0.290 |
Why?
|
| Thinness | 3 | 2024 | 44 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 3 | 2025 | 113 | 0.290 |
Why?
|
| Social Support | 3 | 2017 | 372 | 0.290 |
Why?
|
| Liver Diseases | 2 | 2022 | 155 | 0.280 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 292 | 0.280 |
Why?
|
| Fibroblasts | 2 | 2025 | 394 | 0.280 |
Why?
|
| Postoperative Complications | 1 | 2015 | 1290 | 0.280 |
Why?
|
| Coronary Stenosis | 3 | 2018 | 39 | 0.280 |
Why?
|
| Choice Behavior | 1 | 2008 | 85 | 0.270 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2019 | 27 | 0.270 |
Why?
|
| Survival Rate | 6 | 2021 | 854 | 0.270 |
Why?
|
| Fruit | 2 | 2025 | 109 | 0.270 |
Why?
|
| Long-Term Care | 1 | 2008 | 177 | 0.260 |
Why?
|
| Insurance, Health | 3 | 2016 | 151 | 0.250 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2025 | 1 | 0.240 |
Why?
|
| Polyneuropathies | 1 | 2025 | 11 | 0.240 |
Why?
|
| Time and Motion Studies | 3 | 2022 | 18 | 0.240 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2025 | 9 | 0.230 |
Why?
|
| Mice, Hairless | 1 | 2025 | 19 | 0.230 |
Why?
|
| Testicular Neoplasms | 1 | 2025 | 35 | 0.230 |
Why?
|
| Fractures, Bone | 2 | 2024 | 143 | 0.230 |
Why?
|
| Odds Ratio | 4 | 2021 | 768 | 0.220 |
Why?
|
| beta Catenin | 1 | 2025 | 96 | 0.220 |
Why?
|
| Survival Analysis | 4 | 2020 | 585 | 0.220 |
Why?
|
| Dermal Fillers | 1 | 2024 | 2 | 0.220 |
Why?
|
| Chemoradiotherapy | 1 | 2025 | 69 | 0.220 |
Why?
|
| Fermentation | 1 | 2025 | 50 | 0.220 |
Why?
|
| Skin Aging | 1 | 2024 | 10 | 0.220 |
Why?
|
| Palliative Care | 2 | 2018 | 235 | 0.220 |
Why?
|
| Face | 1 | 2024 | 36 | 0.220 |
Why?
|
| Acne Vulgaris | 1 | 2024 | 24 | 0.220 |
Why?
|
| Amputees | 1 | 2024 | 3 | 0.220 |
Why?
|
| Vision Disorders | 1 | 2024 | 65 | 0.220 |
Why?
|
| Alopecia | 1 | 2024 | 27 | 0.220 |
Why?
|
| Anthracyclines | 1 | 2024 | 11 | 0.210 |
Why?
|
| Diabetes Complications | 2 | 2021 | 107 | 0.210 |
Why?
|
| Migraine Disorders | 1 | 2024 | 41 | 0.210 |
Why?
|
| Patient Satisfaction | 3 | 2018 | 436 | 0.210 |
Why?
|
| Socioeconomic Factors | 5 | 2019 | 784 | 0.210 |
Why?
|
| Spine | 1 | 2024 | 49 | 0.210 |
Why?
|
| Visual Acuity | 1 | 2024 | 127 | 0.210 |
Why?
|
| Hair | 1 | 2024 | 83 | 0.210 |
Why?
|
| Internet | 2 | 2024 | 469 | 0.200 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 77 | 0.200 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 163 | 0.200 |
Why?
|
| Spinal Fractures | 1 | 2023 | 36 | 0.200 |
Why?
|
| Blindness | 1 | 2023 | 42 | 0.200 |
Why?
|
| Neuropsychological Tests | 1 | 2025 | 393 | 0.200 |
Why?
|
| Contraceptives, Oral | 1 | 2023 | 23 | 0.200 |
Why?
|
| Smokers | 1 | 2024 | 119 | 0.200 |
Why?
|
| Menarche | 1 | 2023 | 37 | 0.200 |
Why?
|
| NF-kappa B | 1 | 2025 | 469 | 0.200 |
Why?
|
| Graves Disease | 1 | 2022 | 16 | 0.200 |
Why?
|
| Antirheumatic Agents | 1 | 2025 | 221 | 0.190 |
Why?
|
| Suicide | 1 | 2024 | 134 | 0.190 |
Why?
|
| Prediabetic State | 1 | 2023 | 53 | 0.190 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2022 | 16 | 0.190 |
Why?
|
| Phosphorylation | 1 | 2025 | 937 | 0.190 |
Why?
|
| Bile Duct Neoplasms | 1 | 2022 | 55 | 0.190 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2023 | 111 | 0.190 |
Why?
|
| Smoking Reduction | 1 | 2022 | 3 | 0.190 |
Why?
|
| Enzyme Inhibitors | 1 | 2024 | 373 | 0.190 |
Why?
|
| Frail Elderly | 1 | 2023 | 109 | 0.190 |
Why?
|
| Bone Density | 1 | 2022 | 134 | 0.180 |
Why?
|
| Weight Loss | 1 | 2024 | 274 | 0.180 |
Why?
|
| Coronary Angiography | 3 | 2018 | 206 | 0.180 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 507 | 0.180 |
Why?
|
| Self Report | 3 | 2023 | 381 | 0.180 |
Why?
|
| Chronic Disease | 2 | 2022 | 753 | 0.180 |
Why?
|
| Heart Diseases | 1 | 2024 | 218 | 0.180 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 25 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 33 | 0.170 |
Why?
|
| Health Surveys | 3 | 2021 | 313 | 0.170 |
Why?
|
| Lung Diseases | 1 | 2022 | 183 | 0.170 |
Why?
|
| Mobility Limitation | 1 | 2021 | 49 | 0.170 |
Why?
|
| Health Care Surveys | 2 | 2019 | 286 | 0.170 |
Why?
|
| Korea | 4 | 2017 | 9 | 0.170 |
Why?
|
| Metformin | 1 | 2021 | 74 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2015 | 485 | 0.160 |
Why?
|
| Population Surveillance | 1 | 2021 | 208 | 0.160 |
Why?
|
| Genitalia, Female | 1 | 2020 | 17 | 0.160 |
Why?
|
| Aspirin | 1 | 2021 | 172 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 167 | 0.160 |
Why?
|
| Cholesterol | 1 | 2021 | 259 | 0.160 |
Why?
|
| Genetic Fitness | 1 | 2020 | 34 | 0.160 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 350 | 0.160 |
Why?
|
| Leiomyoma | 1 | 2019 | 18 | 0.150 |
Why?
|
| Family Relations | 1 | 2019 | 24 | 0.150 |
Why?
|
| Anemia | 1 | 2020 | 127 | 0.150 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 34 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2019 | 5669 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2019 | 67 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 28 | 0.150 |
Why?
|
| Liver Cirrhosis | 2 | 2024 | 173 | 0.150 |
Why?
|
| Workload | 1 | 2019 | 129 | 0.150 |
Why?
|
| Communication Disorders | 1 | 2018 | 17 | 0.150 |
Why?
|
| Infant | 1 | 2023 | 1654 | 0.150 |
Why?
|
| Religion and Medicine | 1 | 2018 | 19 | 0.140 |
Why?
|
| Communications Media | 1 | 2018 | 4 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2018 | 64 | 0.140 |
Why?
|
| Exercise Test | 1 | 2020 | 252 | 0.140 |
Why?
|
| Drug Therapy | 1 | 2018 | 56 | 0.140 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 61 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2024 | 3302 | 0.140 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2018 | 47 | 0.140 |
Why?
|
| Aquaporin 4 | 1 | 2018 | 2 | 0.140 |
Why?
|
| Aortography | 1 | 2018 | 60 | 0.140 |
Why?
|
| Aorta, Abdominal | 1 | 2018 | 59 | 0.140 |
Why?
|
| Incidental Findings | 1 | 2018 | 45 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 864 | 0.140 |
Why?
|
| Family Health | 2 | 2015 | 69 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 189 | 0.140 |
Why?
|
| Social Isolation | 1 | 2018 | 36 | 0.140 |
Why?
|
| Prostatectomy | 1 | 2018 | 99 | 0.140 |
Why?
|
| Crime Victims | 1 | 2018 | 35 | 0.140 |
Why?
|
| Burnout, Professional | 1 | 2019 | 134 | 0.140 |
Why?
|
| Aortic Diseases | 1 | 2018 | 70 | 0.130 |
Why?
|
| Logistic Models | 5 | 2019 | 1275 | 0.130 |
Why?
|
| Brain Infarction | 1 | 2017 | 21 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 141 | 0.130 |
Why?
|
| Hospitalization | 3 | 2024 | 1361 | 0.130 |
Why?
|
| Tobacco, Smokeless | 1 | 2017 | 9 | 0.130 |
Why?
|
| Peer Group | 1 | 2018 | 104 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 126 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2018 | 134 | 0.130 |
Why?
|
| Stroke, Lacunar | 1 | 2016 | 4 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 1093 | 0.130 |
Why?
|
| Cause of Death | 4 | 2022 | 221 | 0.130 |
Why?
|
| Goals | 1 | 2017 | 90 | 0.130 |
Why?
|
| Harm Reduction | 1 | 2017 | 33 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2017 | 202 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2018 | 153 | 0.130 |
Why?
|
| Cerebral Hemorrhage | 1 | 2017 | 98 | 0.120 |
Why?
|
| Transaminases | 1 | 2016 | 14 | 0.120 |
Why?
|
| Disease | 1 | 2016 | 27 | 0.120 |
Why?
|
| Tobacco Products | 1 | 2017 | 80 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 163 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 460 | 0.120 |
Why?
|
| Fitness Trackers | 1 | 2015 | 20 | 0.120 |
Why?
|
| Complementary Therapies | 1 | 2016 | 62 | 0.120 |
Why?
|
| Mental Disorders | 2 | 2024 | 794 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 58 | 0.120 |
Why?
|
| Kidney Diseases | 1 | 2017 | 180 | 0.120 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2015 | 13 | 0.120 |
Why?
|
| Prescription Drugs | 1 | 2016 | 51 | 0.120 |
Why?
|
| Urological Agents | 1 | 2015 | 2 | 0.120 |
Why?
|
| Physician's Role | 1 | 2016 | 124 | 0.120 |
Why?
|
| Public Opinion | 1 | 2015 | 25 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 197 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2015 | 42 | 0.110 |
Why?
|
| Tape Recording | 1 | 2014 | 13 | 0.110 |
Why?
|
| Coronary Vessels | 1 | 2015 | 120 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 79 | 0.110 |
Why?
|
| Universities | 1 | 2015 | 161 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 102 | 0.110 |
Why?
|
| Self Concept | 1 | 2015 | 112 | 0.110 |
Why?
|
| Consumer Behavior | 1 | 2014 | 38 | 0.110 |
Why?
|
| Neutrophils | 1 | 2017 | 376 | 0.110 |
Why?
|
| Social Perception | 1 | 2014 | 41 | 0.110 |
Why?
|
| Prevalence | 4 | 2021 | 1387 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 172 | 0.110 |
Why?
|
| NADPH Oxidases | 1 | 2014 | 69 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2015 | 141 | 0.110 |
Why?
|
| Tobacco Use Disorder | 1 | 2017 | 246 | 0.110 |
Why?
|
| Keratinocytes | 1 | 2014 | 63 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2016 | 204 | 0.110 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 70 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 89 | 0.110 |
Why?
|
| Gender Identity | 1 | 2014 | 68 | 0.110 |
Why?
|
| Patient Simulation | 1 | 2014 | 72 | 0.110 |
Why?
|
| Empathy | 1 | 2014 | 67 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 316 | 0.110 |
Why?
|
| Cognition | 1 | 2018 | 484 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2015 | 202 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2015 | 162 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 131 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 347 | 0.110 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 168 | 0.110 |
Why?
|
| Overweight | 3 | 2023 | 251 | 0.110 |
Why?
|
| Testosterone | 1 | 2014 | 121 | 0.100 |
Why?
|
| Educational Status | 1 | 2015 | 278 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 182 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 467 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 127 | 0.100 |
Why?
|
| Stereotyping | 1 | 2013 | 19 | 0.100 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 63 | 0.100 |
Why?
|
| Autophagy | 1 | 2016 | 225 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 456 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2016 | 412 | 0.100 |
Why?
|
| Nerve Growth Factor | 1 | 2013 | 5 | 0.100 |
Why?
|
| Prejudice | 1 | 2013 | 62 | 0.100 |
Why?
|
| Nutrition Surveys | 2 | 2024 | 142 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2015 | 305 | 0.100 |
Why?
|
| Social Stigma | 1 | 2013 | 73 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2014 | 246 | 0.100 |
Why?
|
| Electrocardiography | 1 | 2015 | 552 | 0.100 |
Why?
|
| Family Practice | 1 | 2014 | 212 | 0.100 |
Why?
|
| Aging | 1 | 2018 | 745 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2014 | 531 | 0.090 |
Why?
|
| Alcoholism | 1 | 2015 | 317 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2021 | 937 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 171 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2016 | 519 | 0.090 |
Why?
|
| Animals | 3 | 2025 | 20698 | 0.090 |
Why?
|
| Mice | 1 | 2025 | 10850 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 662 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 723 | 0.090 |
Why?
|
| Algorithms | 1 | 2016 | 1005 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 346 | 0.080 |
Why?
|
| Asthma | 1 | 2015 | 466 | 0.080 |
Why?
|
| Biomarkers | 1 | 2016 | 1407 | 0.080 |
Why?
|
| Risk | 2 | 2025 | 378 | 0.080 |
Why?
|
| Geriatric Assessment | 2 | 2021 | 163 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 791 | 0.070 |
Why?
|
| Housing for the Elderly | 1 | 2008 | 3 | 0.070 |
Why?
|
| Social Values | 1 | 2008 | 16 | 0.070 |
Why?
|
| Anthropology, Cultural | 1 | 2008 | 11 | 0.070 |
Why?
|
| Institutionalization | 1 | 2008 | 23 | 0.070 |
Why?
|
| Intergenerational Relations | 1 | 2008 | 6 | 0.070 |
Why?
|
| Chicago | 1 | 2008 | 26 | 0.070 |
Why?
|
| Adult Children | 1 | 2008 | 6 | 0.070 |
Why?
|
| Depressive Disorder | 2 | 2024 | 286 | 0.070 |
Why?
|
| Bed Rest | 1 | 2008 | 11 | 0.070 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 53 | 0.070 |
Why?
|
| Acculturation | 1 | 2008 | 38 | 0.070 |
Why?
|
| Social Class | 2 | 2022 | 136 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2023 | 498 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 1666 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2008 | 219 | 0.060 |
Why?
|
| Calcium | 2 | 2023 | 576 | 0.060 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2018 | 33 | 0.060 |
Why?
|
| Asymptomatic Diseases | 2 | 2018 | 47 | 0.060 |
Why?
|
| Liver Function Tests | 2 | 2016 | 40 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2023 | 2188 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2025 | 99 | 0.060 |
Why?
|
| Child | 2 | 2025 | 4541 | 0.050 |
Why?
|
| United States | 3 | 2024 | 7852 | 0.050 |
Why?
|
| Stomach | 1 | 2023 | 88 | 0.050 |
Why?
|
| Vitamins | 1 | 2023 | 80 | 0.050 |
Why?
|
| Physical Examination | 1 | 2023 | 111 | 0.050 |
Why?
|
| Vegetables | 1 | 2023 | 69 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 52 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 160 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2008 | 672 | 0.050 |
Why?
|
| Vitamin D | 1 | 2023 | 140 | 0.050 |
Why?
|
| Estrogens | 1 | 2022 | 116 | 0.050 |
Why?
|
| Fear | 1 | 2022 | 70 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2023 | 262 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2023 | 235 | 0.040 |
Why?
|
| State Medicine | 1 | 2020 | 12 | 0.040 |
Why?
|
| Reproductive History | 1 | 2020 | 17 | 0.040 |
Why?
|
| Movement | 1 | 2021 | 156 | 0.040 |
Why?
|
| Gastroscopy | 1 | 2019 | 23 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2020 | 81 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 527 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 220 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 125 | 0.040 |
Why?
|
| Liver | 1 | 2023 | 860 | 0.040 |
Why?
|
| Vaccination | 1 | 2020 | 364 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2020 | 151 | 0.030 |
Why?
|
| Patient Participation | 1 | 2019 | 230 | 0.030 |
Why?
|
| Translations | 1 | 2017 | 6 | 0.030 |
Why?
|
| Independent Living | 1 | 2017 | 52 | 0.030 |
Why?
|
| Culture | 1 | 2017 | 80 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 20 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 49 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2018 | 183 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 197 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 357 | 0.030 |
Why?
|
| Allergy and Immunology | 1 | 2015 | 8 | 0.030 |
Why?
|
| Language | 1 | 2017 | 150 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 331 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 873 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 282 | 0.030 |
Why?
|
| Prescriptions | 1 | 2015 | 33 | 0.030 |
Why?
|
| Probability | 1 | 2015 | 170 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2015 | 158 | 0.030 |
Why?
|
| Pulmonary Medicine | 1 | 2015 | 41 | 0.030 |
Why?
|
| Leukemia | 1 | 2015 | 60 | 0.030 |
Why?
|
| Dual Oxidases | 1 | 2014 | 1 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2016 | 202 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2014 | 78 | 0.030 |
Why?
|
| Health Literacy | 1 | 2015 | 85 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2014 | 13 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 108 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 23 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2014 | 37 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 147 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 172 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 326 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2014 | 3031 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 478 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 312 | 0.030 |
Why?
|
| Chromones | 1 | 2013 | 19 | 0.020 |
Why?
|
| Butadienes | 1 | 2013 | 12 | 0.020 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2013 | 8 | 0.020 |
Why?
|
| Anthracenes | 1 | 2013 | 15 | 0.020 |
Why?
|
| Health Policy | 1 | 2015 | 192 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 59 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 70 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 110 | 0.020 |
Why?
|
| Morpholines | 1 | 2013 | 90 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 373 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 208 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 770 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 2040 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 719 | 0.020 |
Why?
|
| Health Status | 1 | 2012 | 443 | 0.020 |
Why?
|
| Mental Health | 1 | 2012 | 371 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1079 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 878 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 474 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1536 | 0.020 |
Why?
|